CJH Stock Overview
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 2/6 |
CanSino Biologics Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$2.00 |
52 Week High | HK$5.17 |
52 Week Low | HK$1.93 |
Beta | 0.62 |
1 Month Change | -2.05% |
3 Month Change | -20.20% |
1 Year Change | -61.23% |
3 Year Change | -93.37% |
5 Year Change | n/a |
Change since IPO | -57.84% |
Recent News & Updates
Recent updates
Shareholder Returns
CJH | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0% | 1.2% | 2.5% |
1Y | -61.2% | 34.7% | 7.0% |
Return vs Industry: CJH underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: CJH underperformed the German Market which returned 7.3% over the past year.
Price Volatility
CJH volatility | |
---|---|
CJH Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CJH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CJH's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 1,946 | Xuefeng Yu | https://www.cansinotech.com |
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.
CanSino Biologics Inc. Fundamentals Summary
CJH fundamental statistics | |
---|---|
Market cap | €960.05m |
Earnings (TTM) | -€184.97m |
Revenue (TTM) | €45.64m |
10.1x
P/S Ratio-2.5x
P/E RatioIs CJH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CJH income statement (TTM) | |
---|---|
Revenue | CN¥357.08m |
Cost of Revenue | CN¥0 |
Gross Profit | CN¥357.08m |
Other Expenses | CN¥1.80b |
Earnings | -CN¥1.45b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -5.87 |
Gross Margin | 100.00% |
Net Profit Margin | -405.31% |
Debt/Equity Ratio | 43.8% |
How did CJH perform over the long term?
See historical performance and comparison